Corbus Pharmaceuticals Holding (CRBP) - Total Liabilities
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has total liabilities worth $17.37 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Corbus Pharmaceuticals Holding to track the company's year-over-year net asset growth rate.
Corbus Pharmaceuticals Holding - Total Liabilities Trend (2012–2024)
This chart illustrates how Corbus Pharmaceuticals Holding's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Corbus Pharmaceuticals Holding to measure how efficiently the company converts operating cash flow to free cash.
Corbus Pharmaceuticals Holding Competitors by Total Liabilities
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
American Rare EARTHS Ltd
AU:ARR
|
Australia | AU$1.22 Million |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
Mexico | MX$407.26 Million |
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
USA | $18.94 Million |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
Germany | €100.04 Million |
|
Parkit Enterprise Inc
V:PKT
|
Canada | CA$153.26 Million |
|
Soc Centrale Bois Scieries Manche SA
PA:CBSM
|
France | €234.68 Million |
|
ADC Therapeutics SA
NYSE:ADCT
|
USA | $507.87 Million |
|
Onde SA
WAR:OND
|
Poland | zł370.55 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Corbus Pharmaceuticals Holding's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Corbus Pharmaceuticals Holding (CRBP) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corbus Pharmaceuticals Holding's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corbus Pharmaceuticals Holding (2012–2024)
The table below shows the annual total liabilities of Corbus Pharmaceuticals Holding from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $13.45 Million | -61.76% |
| 2023-12-31 | $35.18 Million | +5.57% |
| 2022-12-31 | $33.32 Million | -13.72% |
| 2021-12-31 | $38.62 Million | -32.27% |
| 2020-12-31 | $57.02 Million | +32.65% |
| 2019-12-31 | $42.98 Million | +120.83% |
| 2018-12-31 | $19.47 Million | +111.70% |
| 2017-12-31 | $9.19 Million | +2.52% |
| 2016-12-31 | $8.97 Million | +130.55% |
| 2015-12-31 | $3.89 Million | +427.11% |
| 2014-12-31 | $738.04K | -64.67% |
| 2013-12-31 | $2.09 Million | +280883.37% |
| 2012-12-31 | $743.36 | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more